- 1 Distinct clinical and biological characteristics of acute myeloid leukemia with higher
- 2 expression of long noncoding RNA KIAA0125
- 3 Yu-Hung Wang<sup>1,2,\*</sup>, Chien-Chin Lin<sup>1,2,3,\*</sup>, Chia-Lang Hsu<sup>4</sup>, Sheng-Yu Hung<sup>5</sup>, Chi-Yuan Yao<sup>3,5</sup>,
- 4 Sze-Hwei Lee<sup>1,6</sup>, Cheng-Hong Tsai<sup>2</sup>, Hsin-An Hou<sup>2</sup>, Wen-Chien Chou<sup>2,3,@</sup>, Hwei-Fang Tien<sup>2,@</sup>
- <sup>1</sup>Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University,
- 6 Taipei, Taiwan, <sup>2</sup>Division of Hematology, Department of Internal Medicine, <sup>3</sup>Department of
- 7 Laboratory Medicine, <sup>4</sup>Department of Medical Research, National Taiwan University Hospital,
- 8 Taipei, Taiwan, <sup>5</sup>Division of Hematology, Department of Internal Medicine, National Taiwan
- 9 University Hospital Yunlin Branch, Yunlin, Taiwan, <sup>6</sup>Tai-Cheng Stem Cell Therapy Center,
- 10 National Taiwan University, Taipei, Taiwan
- \*Yu-Hung Wang and Chien-Chin Lin contribute equally to this study.
- 12 **Correspondence:** Dr. Wen-Chien Chou, Department of Laboratory Medicine, National
- 13 Taiwan University Hospital, No. 7, Chung-Shan S. Rd., Taipei City 10002, Taiwan; E-mail:
- wchou@ntu.edu.tw; Tel: +886-2-23123456; or Dr. Hwei-Fang Tien, Department of Internal
- 15 Medicine, National Taiwan University Hospital, No. 7, Chung-Shan S. Rd., Taipei City 10002,
- 16 Taiwan; E-mail: hftien@ntu.edu.tw; Tel: +886-2-23123456.

#### 18 Abstract

- 19 Expression of long non-coding RNA KIAA0125 has been incorporated in various gene
- 20 expression signatures for prognostic prediction in acute myeloid leukemia (AML) patients,
- yet its functions and clinical significance remain unclear. This study was aimed to investigate

  NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23

24

25

26

27

28

29

30

31

32

33

34

35

36

the clinical and biological characteristics of AML bearing different levels of KIAA0125. We profiled KIAA0125 expression levels in bone marrow cells from 347 de novo AML patients and found higher KIAA0125 expression was closely associated with FLT3-ITD, RUNX1, and DNMT3A mutations, and M1 subtype by the French-American-British classification, but inversely correlated with t(8;21) and t(15;17). Among the 227 patients who received standard chemotherapy, those with higher KIAA0125 expression had a lower complete remission rate, shorter overall survival (OS) and disease-free survival (DFS) than those with lower expression. The prognostic significance was validated in both TCGA and GSE12417 cohorts. Subgroup analyses showed that higher KIAA0125 expression also predicted shorter DFS and OS in patients with normal karyotype or non-M3 AML. In multivariable analysis, higher KIAA0125 expression remained an adverse risk factor independent of age, WBC counts, karyotypes, and mutation patterns. Bioinformatics analyses revealed that higher KIAA0125 expression was associated with hematopoietic and leukemic stem cell signatures and ATP-binding cassette transporters, two predisposing factors for chemoresistance.

#### Introduction

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

Long non-coding RNAs (IncRNAs) are non-protein coding RNAs that are longer than 200 nucleotides. Comparing to other classes of ncRNAs, IncRNAs exhibit a wide range of structures and functions[1]. Recently, IncRNAs have emerged as important regulators for gene expression via remodeling nuclear architecture, modulating mRNA stability and translation, and post-translational modifications[1-4]. Besides, some IncRNAs are dysregulated and harbor prognostic relevance in several types of cancers [5-8]. However, the roles of IncRNAs in tumorigenesis are still largely unknown. In recent years, several gene expression-based prognostic scores have been developed for better risk stratification of acute myeloid leukemia (AML) patients[9-14]. Among those high-risk genes, IncRNA gene KIAA0125 (also named as FAM30A) is unique because it is the only non-coding gene and is expressed in humans but not in mice (From the UniProt database, https://www.uniprot.org/uniprot/Q9NZY2). Additionally, KIAA0125 expression was integrated into a recently proposed 17-gene stemness score, which could predict outcomes in AML patients[9]. In this study, we aimed to investigate the association of KIAA0125 expression with clinical and biological characteristics in AML patients. We first profiled the expression levels of KIAA0125 in bone marrow (BM) cells from AML patients and normal controls and demonstrated that AML patients had higher KIAA0125 expression than normal controls. Higher expression of KIAA0125 was associated with distinct clinical and biological characteristics and served as an independent poor prognostic biomarker for AML patients in ours and two other publicly annotated cohorts. Further bioinformatics analyses showed that higher expression of *KIAA0125* in AML was closely associated with hematopoietic stem cell (HSC) and leukemic stem cell (LSC) signatures and several important ATP-binding cassette transporters (ABC transporters); these factors are regarded responsible for chemoresistance in AML. *KIAA0125* could be a potential target for novel treatment in AML patients with high *KIAA0125* expression.

#### **Materials and Methods**

#### Patients

We recruited 347 adult patients with *de novo* AML diagnosed in the National Taiwan

University Hospital (NTUH) from 1996 to 2011 who had enough cryopreserved BM cells for tests. The diagnoses were based on the French–American–British (FAB) and the 2016 World Health Organization classifications[15, 16]. Among them, 227 patients received standard chemotherapy. Non M3 (acute promyelocytic leukemia, APL) patients received idarubicin 12 mg/m² per day days 1-3 and cytarabine 100 mg/m² per day days 1-7, and then consolidation chemotherapy with 2-4 courses of high-dose cytarabine 2000 mg/m² q12h for total 8 doses, with or without an anthracycline (Idarubicin or Mitoxantrone), after achieving complete remission (CR) as described previously[17]. APL patients received concurrent all-trans retinoic acid and chemotherapy. The remaining 120 patients received supportive care and/or reduced-intensity anti-leukemia therapy due to underlying comorbidities or based on the decision of the physicians or patients. BM samples from 30 healthy donors of hematopoietic

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

stem cell transplantation (HSCT) were collected as normal controls. This study was approved by the Institutional Review Board of the NTUH. Microarray and genetic alteration analysis We profiled the global gene expression of BM mononuclear cells from 347 AML patients and 30 healthy transplant donors by Affymetrix GeneChip Human Transcriptome Array 2.0 as described previously[11, 18, 19]. The raw and normalized microarray data reported in this article have been deposited in the Gene Expression Omnibus database (accession number GSE68469 and GSE71014)[11, 18, 19]. For external validation, we analyzed microarray datasets of GSE12662 (n=76) and GSE12417-GPL96 cohorts (n=163), and RNAseq dataset of the TCGA cohort (n=186)[20-22]. Cytogenetic analyses were performed and interpreted as described previously [23]. We also analyzed the mutation statuses of 17 myeloid-relevant genes including ASXL1, IDH1, IDH2, TET2, DNMT3A, FLT3-ITD, FLT3-TKD, KIT, NRAS, KRAS, RUNX1, MLL/PTD, CEBPA, NPM1, PTPN11, TP53, and WT1 by Sanger sequencing as previously described [17, 18, 23-26]. Analysis of gene expression in next-generation sequencing datasets We analyzed gene expression data of 141 AML samples profiled with Illumina Genome Analyzer RNA Sequencing in the TCGA database [22] to investigate the absolute gene expression levels. **Gene Set Enrichment Analysis** The preranked Gene Set Enrichment Analysis (GSEA) implemented by R package clusterProfiler was performed using the stem cell-related gene sets from the MSigDB

databases. The genes were ranked based on the Spearman's correlation coefficient between the given gene and *KIAA0125*.

#### Statistical analysis

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

We used the Mann-Whitney U test to compare continuous variables and medians of distributions. The Fisher exact test or the  $\chi 2$  test were performed to examine the difference in discrete variables, including gender, FAB classification, cytogenetic changes, and genetic alterations between patients with lower and higher KIAA0125 expression. Overall survival (OS) was the duration from the date of initial diagnosis to the time of last follow-up or death from any cause, whichever occurred first. Disease free survival (DFS) was the duration from the date of attaining leukemia-free state until the date of AML relapse or death from any cause, whichever occurred first. The survival prediction power of KIAA0125 expression was evaluated by both the log-rank test and the univariate Cox proportional hazards model. We plotted the survival curves with Kaplan-Meier analysis and calculated the statistical significance with the log-rank test. The Cox proportional hazards model was used in multivariable regression analysis. P values < 0.05 were considered statistically significant. All statistical analyses were performed with BRB-ArrayTools (version 4.5.1; Biometric Research Branch, National Cancer Institute, Rockville, MD), and IBM SPSS Statistics 23 for Windows.

#### Results

The median age of the 347 AML patients was 57 years. Among the 331 patients who had cytogenetic data at diagnosis, 165 (49.8%) had clonal chromosomal abnormalities. Sixty

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

patients (18.1%) had favorable cytogenetics; 223 (67.2%), intermediate-risk cytogenetics; and 14.8%, unfavorable cytogenetics (Supplement Table 1) based on the refined British Medical Research Council (MRC) classification [27]. The clinical and laboratory characteristics of these patients at diagnosis are summarized in Table 1. Comparison of clinical characteristics and genetic alterations between patients with higher and lower KIAA0125 expression We first compared the BM KIAA0125 expression between the 30 healthy controls and 347 AML patients. The expression of KIAA0125 was significantly higher in AML samples than healthy controls (p<0.001, Figure 1a). Then, the 347 AML patients were divided into two groups by the median value of the KIAA0125 expression. The comparison of clinical and laboratory features between the two groups is shown in Table 1. The higher-KIAA0125 group had higher circulating blasts at diagnosis (p=0.021) and higher incidence of FAB M1 subtype (p<0.001), but lower incidence of M3 subtype (p<0.001), compared to the lower-KIAA0125 group (Table 1). Patients with FAB immature subtype of M0 or M1 had higher KIAA0125 expression while those with M3 subtype had lower expression of KIAA0125 (p<0.001, Figure 1c), and similar results were noted in the GSE12662 cohort (p<0.001, Figure 1d). Moreover, higher-KIAA0125 patients had significantly lower frequencies of t(8;21) and t(15;17) in both NTUH cohort (both p<0.001, Supplement Table 1) and TCGA cohort (p=0.006and p<0.001, respectively, Supplement Table 1). The higher-KIAA0125 patients more frequently had FLT3-ITD (p=0.048) and mutations in DNMT3A (p=0.015), and RUNX1 (p=0.034) (Supplement Table 2). Compatible with this finding, patients with

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

DNMT3A or RUNX1 mutation had higher KIAA0125 expression than those without the mutation (p=0.019 and 0.045, respectively, Supplement Figure 1). Similarly, there was close association between higher KIAA0125 expression and DNMT3A (p=0.001) and RUNX1 mutations (p=0.017) in the TCGA cohort (Supplement Table 3). Among the 227 patients who received standard chemotherapy, 166 (73.1%) patients attained a complete remission (CR) while 43 (18.9%) patients had primary refractory diseases. Notably, the patients with higher KIAA0125 expression had a lower CR rate (61.2% vs. 84.7%, p<0.001) than those with lower expression. In accordance with this finding, the patients who achieved CR after induction chemotherapy had lower expression of BM KIAA0125 at diagnosis than those who did not (p<0.001, Figure 1b). The impacts of the KIAA0125 expression on OS and DFS Patients with higher KIAA0125 expression had an inferior DFS and OS than those with lower expression, no matter whether the survival was censored on the day of hematopoietic stem cell transplantation (HSCT) (median, 11.7 months vs. 101.7 months, p<0.001; and 20 months vs not reached (NR), p=0.001, respectively; Figure 2a and 2b) or not (p=0.001 and p=0.001, respectively; Supplement Figure 2a and 2b). Subgroup analyses showed that the prognostic significance of KIAA0125 expression for DFS and OS remained valid in both non-APL and normal karyotype patients (Figure 2c and 2d). In multivariable analysis, we included clinically relevant parameters and variables with a p-value < 0.05 in univariate Cox regression analysis (Supplement Table 4) as covariates, including age, white blood cell counts at diagnosis, karyotypes, mutation statuses

of NPM1/FLT3-ITD,  $CEBPA^{double mutations}$ , RUNX1, MLL-PTD, and TP53, and KIAA0125 expression. Higher KIAA0125 expression, either divided by a median (Table 2) or calculated as continuous values (Supplement Table 5), was an independent adverse prognostic factor for DFS (p<0.001 and p<0.001, respectively) and OS (p=0.002 and p=0.001, respectively). To verify the prognostication power of the KIAA0125 expression, we analyzed the expression of KIAA0125 and its prognostic significance in the TCGA cohort and the GSE12417-GPL96 cohort. Consistent with the findings in the NTUH cohort, patients with higher KIAA0125 expressions had a significantly shorter OS (12.2 months vs. 27.4 months, p=0.004, and 7.8 months vs. 33.3 months, p<0.001, respectively, Figure 2e and 2f) than those with lower KIAA0125 expression in the two external validation cohorts.

#### Biological impacts of KIAA0125 in AML

To gain biological insights into the underlying mechanism of unfavorable prognosis related to *KIAA0125* overexpression, we investigated the genes whose expression are strongly correlated with that of *KIAA0125*. Since *KIAA0125* was reported as an LSC marker, we curated several published HSC and LSC signatures from different studies[28-30]. GSEA showed HSC and LSC signatures were all significantly enriched in the patients with higher *KIAA0125* expression in both the NTUH and TCGA cohorts (both *p*<0.001, Figure 3a). We next checked the leading-edge genes whose expression levels were most positively correlated to *KIAA0125* expression in both NTUH and TCGA cohort. Among them, *SPINK2*, *MAP7*, *HOPX*, *MMRN1*, *DNMT3B*, *TCF4*, *SLC38A1*, *DOCK1*, *ARHGAP22*, *MN1*, and 4 genes in the ATP-binding cassette (ABC) superfamily (*ABCG1*, *ABCA2*, *ABCB1*, and *ABCC1*) have been

reported to be associated with poor prognosis or chemoresistance in AML (Figure 3b and Table 3)[9, 31-50].

#### Discussion

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

AML cells have abnormal genetic background, either mutations or aberrant expression of specific genes. In recent years, several gene expression scores have been proposed for prognostic prediction of AML patients. We previously developed a 11-gene mRNA expression signature, including AIF1L, CXCR7, DNTT, GPR56, H1F0, IFITM3, KIAA0125, MX1, STAB1, TM4SF1 and TNS3, for prognostication in AML patients[11]. Another group built a six-gene leukemia stem cell (LSC) score with the incorporation of DNMT3B, GPR56, CD34, SOCS2, SPINK2, and KIAA0125 expressions for pediatric AML[32]. Recently, Ng et al. proposed a 17-gene LSC score that incorporated expressions of 17 stemness-related genes, including KIAA0125, and showed the scoring system was powerful to predict prognosis in AML patients[9]. Among these prognostic-relevant genes, KIAA0125 is the only non-coding gene and expressed only in the homo sapiens, but not in mice. KIAA0125 is located on chromosome 14 of the human genome. It was reported to be upregulated in amelobalstoma but shown as a tumor suppressor gene in colorectal cancer[51, 52]. However, its role in tumorigenesis is still largely unknown. In this study, we found that the expression level of KIAA0125 in BM was significantly higher in AML patients than normal HSC transplant donors. The expression of KIAA0125 was lower in the mature subtype M3, but higher in more immature subtypes, M0 and M1, compatible with the

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

finding that it is an LSC-related gene[20]. The similar finding could be seen in the GSE 12662 cohort. Further bioinformatics study also showed highly significant association of KIAA0125 expression with stem cell signatures, either HSC or LSC. We found that expressions of SPINK2, MAP7, HOPX, MMRN1, DNMT3B, TCF4, SLC38A1, DOCK1, ARHGAP22, MN1, and 4 genes in the ATP-binding cassette (ABC) superfamily (ABCG1, ABCA2, ABCB1, and ABCC1), which have been reported to be associated with poor prognosis or chemoresistance in AML, were positively correlated to higher expression of KIAA0125 (Figure 3b and Table 3). HOPX, DOCK1, DNMT3B, MMRN1, and ARHGAP22 genes were reported as important leukemia stem cell markers[9, 34, 35, 37, 42]. Higher SPINK2 expression was associated with poor prognosis in adult and pediatric AML[31, 32]. TCF4 expression could predict outcome in RUNX1-mutated and translocated AML[39, 40]. MN1 overexpression could induce AML in mice and predict ATRA resistance in human AML patients [43, 44]. Current knowledge about the association between theses KIAA0125-correlated genes and AML is summarized in Table 3. Interestingly, the expression levels of several ABC transporter genes, including ABCA2, ABCB1, ABCC1, and ABCG1, were also significantly higher in AML patients with higher KIAA0125 expression. The ABC transporter family consists of 48 proteins in subfamilies designated A to G and some of them are known to be associated with multidrug resistance via ATP-dependent drug efflux[45, 46, 49]. ABCB1, ABCC1 and ABCG1 were reported to be responsible for chemoresistance in AML[45, 48]. The translational expression of ABCA2 was shown to be a prognostic marker for drug resistance in pediatric acute lymphoblastic

226

227

228

229

230

231

232

233

234

235

236

237

238

leukemia[47, 50]. The underlying mechanistic basis of the high correlation of these 4 genes to the expression of KIAA0125 warrants further studies. To the best of our knowledge, this is by far the first study specifically addressing the expression of lncRNA KIAA0125 and its clinical and biological associations in AML patients. We found that higher KIAA0125 expression were closely associated with RUNX1 and DNMT3A1 mutations in both the NTUH and TCGA cohorts. Patients with higher KIAA0125 expression were more refractory to chemotherapy with a lower CR rate and higher refractory rate (Table 1). They had shorter OS and DFS not only among total cohort, but also in subgroups of patients with non-APL and those with normal karyotype. Based on its important clinical significance, KIAA0125 could be a potential therapeutic target for AML and might give some directives to future work. Further experimental studies are necessary to delineate how KIAA0125 participates in the stem cell biology of hematopoietic lineages and its role in the pathogenesis in AML.

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

**Acknowledgements** We would like to acknowledge the service provided by Department of Laboratory Medicine, Department of Medical Research, and Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital. **Authorship Contributions** YHW and CCL contribute equally to this study. YHW and CCL were responsible for data collection and management, statistical analysis and interpretation, literature research, and manuscript writing; SYH and CYY were responsible for data management and statistical analysis; CLH assisted in statistical analysis; SHL, CHT and HAH was responsible for data collection and management; and WCC and HFT planned, designed, and coordinated the study over the entire period and wrote the manuscript. **Disclosure of Conflicts of Interest** The authors declare that they have no competing interests. **Funding** The study was supported by grants from Ministry of Health and Welfare, Taiwan (project number: MOHW107-TDU-B-211-114009) and Ministry of Science and Technology, Taiwan (project number: MOST 107-2314-B-002-013 and MOST 108-2314-B-002-011).

#### Reference

- 1. Fatica, A. and I. Bozzoni, Long non-coding RNAs: new players in cell differentiation
- 259 and development. Nat Rev Genet, 2014. **15**(1): p. 7-21.
- 260 2. Wilusz, J.E., H. Sunwoo, and D.L. Spector, Long noncoding RNAs: functional surprises
- 261 from the RNA world. Genes Dev, 2009. **23**(13): p. 1494-504.
- 3. Kung, J.T., D. Colognori, and J.T. Lee, Long noncoding RNAs: past, present, and future.
- 263 Genetics, 2013. **193**(3): p. 651-69.
- 4. Mercer, T.R., M.E. Dinger, and J.S. Mattick, Long non-coding RNAs: insights into
- 265 functions. Nat Rev Genet, 2009. **10**(3): p. 155-9.
- 266 5. Lin, C. and L. Yang, Long Noncoding RNA in Cancer: Wiring Signaling Circuitry. Trends
- 267 Cell Biol, 2018. **28**(4): p. 287-301.
- 268 6. Prensner, J.R. and A.M. Chinnaiyan, *The emergence of lncRNAs in cancer biology.*
- 269 Cancer Discov, 2011. **1**(5): p. 391-407.
- 7. Huarte, M., The emerging role of IncRNAs in cancer. Nat Med, 2015. 21(11): p.
- 271 1253-61.
- 272 8. Cheetham, S.W., et al., Long noncoding RNAs and the genetics of cancer. Br J Cancer,
- 273 2013. **108**(12): p. 2419-25.
- 274 9. Ng, S.W., et al., A 17-gene stemness score for rapid determination of risk in acute
- 275 *leukaemia*. Nature, 2016. **540**(7633): p. 433-437.
- 276 10. Metzeler, K.H., et al., An 86-probe-set gene-expression signature predicts survival in
- 277 cytogenetically normal acute myeloid leukemia. Blood, 2008. **112**(10): p. 4193-201.
- 278 11. Chuang, M.K., et al., An mRNA expression signature for prognostication in de novo
- acute myeloid leukemia patients with normal karyotype. Oncotarget, 2015. **6**(36): p.
- 280 39098-110.
- 281 12. Wilop, S., et al., A three-gene expression-based risk score can refine the European
- 282 LeukemiaNet AML classification. J Hematol Oncol, 2016. 9(1): p. 78.
- 283 13. Marcucci, G., et al., Epigenetics meets genetics in acute myeloid leukemia: clinical
- impact of a novel seven-gene score. J Clin Oncol, 2014. **32**(6): p. 548-56.
- 285 14. Li, Z., et al., Identification of a 24-gene prognostic signature that improves the
- 286 European LeukemiaNet risk classification of acute myeloid leukemia: an international
- 287 collaborative study. J Clin Oncol, 2013. **31**(9): p. 1172-81.
- 288 15. Arber, D.A., et al., The 2016 revision to the World Health Organization classification
- of myeloid neoplasms and acute leukemia. Blood, 2016. **127**(20): p. 2391-405.
- 290 16. Bennett, J.M., et al., *Proposals for the classification of the acute leukaemias*.
- 291 French-American-British (FAB) co-operative group. Br J Haematol, 1976. **33**(4): p.
- 292 451-8.
- 293 17. Tang, J.L., et al., AML1/RUNX1 mutations in 470 adult patients with de novo acute
- myeloid leukemia: prognostic implication and interaction with other gene alterations.
- 295 Blood, 2009. **114**(26): p. 5352-61.

- 296 18. Chiu, Y.C., et al., Prognostic significance of NPM1 mutation-modulated
- 297 microRNA-mRNA regulation in acute myeloid leukemia. Leukemia, 2016. **30**(2): p.
- 298 274-84.
- 299 19. Chuang, M.K., et al., A 3-microRNA scoring system for prognostication in de novo
- acute myeloid leukemia patients. Leukemia, 2015. **29**(5): p. 1051-9.
- 301 20. Payton, J.E., et al., High throughput digital quantification of mRNA abundance in
- primary human acute myeloid leukemia samples. J Clin Invest, 2009. **119**(6): p.
- 303 1714-26.
- 304 21. Metzeler, K.H., et al., An 86-probe-set gene-expression signature predicts survival in
- 305 cytogenetically normal acute myeloid leukemia. Blood, 2008. **112**(10): p. 4193-201.
- 22. Ley, T.J., et al., Genomic and epigenomic landscapes of adult de novo acute myeloid
- 307 leukemia. N Engl J Med, 2013. **368**(22): p. 2059-74.
- 308 23. Chou, W.C., et al., TET2 mutation is an unfavorable prognostic factor in acute myeloid
- leukemia patients with intermediate-risk cytogenetics. Blood, 2011. **118**(14): p.
- 310 3803-10.
- 311 24. Chou, W.C., et al., Distinct clinical and biologic characteristics in adult acute myeloid
- leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 2010. **115**(14): p.
- 313 2749-54.
- 314 25. Chou, W.C., et al., Distinct clinical and biological features of de novo acute myeloid
- leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood, 2010. **116**(20): p.
- 316 4086-94.
- 317 26. Hou, H.A., et al., Integration of cytogenetic and molecular alterations in risk
- 318 stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia,
- 319 2014. **28**(1): p. 50-8.
- 320 27. Grimwade, D., et al., Refinement of cytogenetic classification in acute myeloid
- leukemia: determination of prognostic significance of rare recurring chromosomal
- 322 abnormalities among 5876 younger adult patients treated in the United Kingdom
- 323 *Medical Research Council trials.* Blood, 2010. **116**(3): p. 354-65.
- 324 28. Eppert, K., et al., Stem cell gene expression programs influence clinical outcome in
- 325 human leukemia. Nat Med, 2011. 17(9): p. 1086-93.
- 326 29. Ivanova, N.B., et al., A stem cell molecular signature. Science, 2002. 298(5593): p.
- 327 601-4.
- 328 30. Jaatinen, T., et al., Global gene expression profile of human cord blood-derived
- 329 *CD133+ cells.* Stem Cells, 2006. **24**(3): p. 631-41.
- 330 31. Xue, C., et al., Elevated SPINK2 gene expression is a predictor of poor prognosis in
- 331 *acute myeloid leukemia.* Oncol Lett, 2019. **18**(3): p. 2877-2884.
- 332 32. Elsayed, A.H., et al., A six-gene leukemic stem cell score identifies high risk pediatric
- 333 *acute myeloid leukemia*. Leukemia, 2020. **34**(3): p. 735-745.
- 334 33. Fu, L., et al., High expression of MAP7 predicts adverse prognosis in young patients

with cytogenetically normal acute myeloid leukemia. Sci Rep, 2016. **6**: p. 34546.

- 336 34. Lin, C.C., et al., Higher HOPX expression is associated with distinct clinical and
- biological features and predicts poor prognosis in de novo acute myeloid leukemia.
- 338 Haematologica, 2017. **102**(6): p. 1044-1053.
- 339 35. Laszlo, G.S., et al., Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute
- 340 Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res,
- 341 2015. **21**(14): p. 3187-95.
- 342 36. Hayette, S., et al., High DNA methyltransferase DNMT3B levels: a poor prognostic
- marker in acute myeloid leukemia. PLoS One, 2012. **7**(12): p. e51527.
- 344 37. Niederwieser, C., et al., Prognostic and biologic significance of DNMT3B expression in
- older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia,
- 346 2015. **29**(3): p. 567-75.
- 347 38. Wong, K.K., C.H. Lawrie, and T.M. Green, Oncogenic Roles and Inhibitors of DNMT1,
- DNMT3A, and DNMT3B in Acute Myeloid Leukaemia. Biomark Insights, 2019. 14: p.
- 349 1177271919846454.
- 350 39. Gerritsen, M., et al., RUNX1 mutations enhance self-renewal and block granulocytic
- differentiation in human in vitro models and primary AMLs. Blood Adv, 2019. **3**(3): p.
- 352 320-332.
- 353 40. In 't Hout, F.E.M., et al., Transcription factor 4 (TCF4) expression predicts clinical
- outcome in RUNX1 mutated and translocated acute myeloid leukemia.
- 355 Haematologica, 2019.
- 356 41. Li, Y., et al., High expression of SLC38A1 predicts poor prognosis in patients with de
- 357 novo acute myeloid leukemia. J Cell Physiol, 2019. **234**(11): p. 20322-20328.
- 358 42. Lee, S.H., et al., High expression of dedicator of cytokinesis 1 (DOCK1) confers poor
- 359 *prognosis in acute myeloid leukemia.* Oncotarget, 2017. **8**(42): p. 72250-72259.
- 360 43. Heuser, M., et al., MN1 overexpression induces acute myeloid leukemia in mice and
- predicts ATRA resistance in patients with AML. Blood, 2007. **110**(5): p. 1639-47.
- 362 44. Heuser, M., et al., Cell of origin in AML: susceptibility to MN1-induced transformation
- is regulated by the MEIS1/AbdB-like HOX protein complex. Cancer Cell, 2011. **20**(1): p.
- 364 39-52.
- 365 45. Choi, Y.H. and A.M. Yu, ABC transporters in multidrug resistance and
- 366 pharmacokinetics, and strategies for drug development. Curr Pharm Des, 2014. 20(5):
- 367 p. 793-807.
- 368 46. Dean, M., The genetics of ATP-binding cassette transporters. Methods Enzymol, 2005.
- **400**: p. 409-29.
- 370 47. Efferth, T., et al., Expression profiling of ATP-binding cassette transporters in
- 371 childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther, 2006. 5(8): p.
- 372 1986-94.
- 373 48. Marzac, C., et al., ATP Binding Cassette transporters associated with chemoresistance:
- 374 transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of

375 *281 acute myeloid leukemia patients.* Haematologica, 2011. **96**(9): p. 1293-301.

376 377	49.	Vasiliou, V., K. Vasiliou, and D.W. Nebert, <i>Human ATP-binding cassette (ABC)</i> transporter family. Hum Genomics, 2009. <b>3</b> (3): p. 281-90.
378	50.	Aberuyi, N., et al., The translational expression of ABCA2 and ABCA3 is a strong
379		prognostic biomarker for multidrug resistance in pediatric acute lymphoblastic
380		<i>leukemia</i> . Onco Targets Ther, 2017. <b>10</b> : p. 3373-3380.
381	51.	Diniz, M.G., et al., The long noncoding RNA KIAA0125 is upregulated in
382		ameloblastomas. Pathol Res Pract, 2019. <b>215</b> (3): p. 466-469.
383	52.	Yang, Y., et al., IncRNA KIAA0125 functions as a tumor suppressor modulating growth
384		and metastasis of colorectal cancer via Wnt/beta-catenin pathway. Cell Biol Int, 2019.
385		
386		
300		

## Table 1. Comparison of clinical and laboratory features between AML patients with lower

## and higher BM KIAA0125 expression

387

388

Clinical characters	Total (N=347)	High <i>KIAA0125</i> (n=174)	Low <i>KIAA0125</i> (n=173)	<i>P</i> value
Sex				0.174
Male	196	92	104	
Female	151	82	69	
Age*		57 (15-91)	58 (18-90)	0.830
Laboratory data*				
WBC, X 10 <sup>9</sup> /L	21.9 (0.38-423)	21.4 (0.38-417.5)	22.38 (0.65-423.0)	0.872
Hb, g/dL	8.1 (3.3-16.2)	8.1 (3.3-13.2)	8.1 (3.7-16.2)	0.959
Platelet, X 10 <sup>9</sup> /L	45 (2-655)	54 (6-455)	41 (2-655)	0.060
Blast, X 10 <sup>9</sup> /L	9.1 (0-369.1)	12.3 (0-345.9)	5.7 (0-369.1)	0.021
LDH (U/L)	917 (202-13130)	892.5 (242-7734)	925 (202-13130)	0.787
FAB classification, n (%)				
M0	6	4 (2.4)	2 (1.2)	0.414
M1	67	48 (28.4)	19 (11.1)	<0.001
M2	109	56 (33.1)	53 (30.8)	0.756
M3	28	3 (1.8)	25 (14.5)	<0.001
M4	103	49 (28.9)	54 (31.4)	0.534
M5	20	6 (3.6)	14 (8.1)	0.063
M6	8	3 (1.8)	5 (2.9)	0.469
Undetermined	6	5	1	0.215
Induction response, n (%)	227	116	111	
CR	165 (72.7)	71 (61.2)	94 (84.7)	<0.001
PR	5 (2.2)	4 (3.4)	1 (0.9)	0.191
Refractory	42 (18.5)	33 (28.4)	9 (8.1)	<0.001
Induction death	15 (6.6)	8 (6.9)	7 (6.3)	0.858
Relapse (%)	72 (31.7)	42 (36.2)	30 (27.0)	0.137

389 Abbreviations: CR, complete remission; Hb, hemoglobin; HSCT, allogeneic hematopoietic stem cell transplantation; LDH,

390 lactate dehydrogenase; PR, partial remission.

391 \*Median (range).

## Table 2. Multivariable analysis for DFS and OS in 227 AML patients who received standard

### intensive chemotherapy

	DFS			OS				
		95% CI				95% CI		
Variable	HR	Lower	Upper	P	HR	Lower	Upper	P
Age*	1.009	0.997	1.021	0.129	1.031	1.014	1.047	<0.001
WBC*	1.004	1.001	1.007	0.002	1.005	1.001	1.008	0.009
Karyotype†	1.762	1.310	2.369	<0.001	1.910	1.288	2.833	0.001
NPM1/FLT3-ITD‡	0.540	0.297	0.981	0.043	0.812	0.404	1.634	0.559
CEBPA double	0.423	0.216	0.830	0.012	0.253	0.077	0.833	0.024
RUNX1	1.463	0.841	2.546	0.178	1.492	0.763	2.914	0.242
MLL-PTD	2.864	1.346	6.094	0.006	3.017	1.136	8.017	0.027
TP53	1.691	0.607	4.705	0.315	2.798	0.875	8.950	0.083
Higher KIAA0125 expression§	2.609	1.760	3.867	<0.001	2.226	1.335	3.711	0.002

395 Abbreviations: HR, hazard ratios; Cl, confidence interval.

†Unfavorable cytogenetics versus others. The classification of favorable, intermediate and unfavorable cytogenetics is based on the refined Medical Research Council (MRC) classification [27]. Favorable: t(15;17)(q22;q21), t(8;21)(q22;q22), and inv(16)(p13q22)/t(16;16)(p13;q22); unfavorable: abn(3q) (excluding t(3;5)(q25;q34)), inv(3)(q21q26)/t(3;3)(q21;q26), add(5q)/del(5q), -5, -7, add(7q)/del(7q), t(6;11)(q27;q23), t(10;11)(p1113;q23), other t(11q23) (excluding t(9;11)(p21~22;q23) and t(11;19)(q23;p13)), t(9;22)(q34;q11), -17, and abn(17p); and intermediate: entities not classified as favorable or adverse. Seven patients without chromosome data were not included in the analysis.

 $$\pm NPM1 + /FLT3 - |TD- versus other subtypes.$ 

§High vs. low expression of KIAA0125 (median as cutoff)

<sup>\*</sup>As continuous variable.

# Table 3. Summary of the biological functions of the KIAA0125-associated genes that have

## been reported to be associated with prognosis or drug resistance in AML patients and

## their correlation values with KIAA0125 in ours and the TCGA cohorts

Genes	Cor	relation co	efficient	(p value)	<ul> <li>Association with leukemia</li> </ul>	
delles	ſ	HUTV	TCGA		Association with feukenna	
					Serine Peptidase Inhibitor; upregulation is associated with poor	
SPINK2	0.661	(3.4E-45)	0.5798	(6.2E-15)	outcomes in adult patients with AML[31]; integrated into a 6-gene	
					LSC score to identifies high risk pediatric AML[32]	
MAP7	0.653	1.0E-43	0.696	( <e-45)< th=""><th>Microtubule-associated proteins, overexpressed in cytogenetically</th></e-45)<>	Microtubule-associated proteins, overexpressed in cytogenetically	
WAL	0.055	1.06-43	0.030	(~E-43)	normal AML patients with dismal outcomes[33]	
НОРХ	0.619	(2.6E-38)	0.643	( <e-45)< th=""><th>The smallest homeodomain protein; higher expression predicts</th></e-45)<>	The smallest homeodomain protein; higher expression predicts	
1101 X	0.013				poor prognosis in <i>de novo</i> AML[34]	
MMRN1	0.609	(9.7E-37)	0.597	( <e-45)< th=""><th>A member of the elastin microfibrillar interface protein; an adverse</th></e-45)<>	A member of the elastin microfibrillar interface protein; an adverse	
	0,000	(5.7 = 5.7)	0,00.	( -=,	marker in both pediatric and adult AML[35]	
DNMT3B	0.599	(1.7E-35)	0.631	( <e-45)< th=""><th>DNA methyltransferases; an important LSC marker[36-38]</th></e-45)<>	DNA methyltransferases; an important LSC marker[36-38]	
TCF4	0.556	(1.1E-29)	0.626	( <e-45)< th=""><th>A transcription factor; predict outcome in RUNX1 mutated and</th></e-45)<>	A transcription factor; predict outcome in RUNX1 mutated and	
	0.000	(1.11 23)			translocated AML[39,40]	
SLC38A1	0.536	(2.3E-27)	0.585	( <e-45)< th=""><th>A glutamine amino acid transporter, overexpressed in AML patients</th></e-45)<>	A glutamine amino acid transporter, overexpressed in AML patients	
020007.12					with adverse clinical outcomes[41]	
DOCK1	0.530	(1.1E-26)	0.597	(5.9E-16)	A novel class of guanine nucleotide exchange factors; high	
					expression confers poor prognosis in AML[42]	
ARHGAP22	0.519	(1.5E-25)	F-25) 0.518	( <e-45)< th=""><th>Rho GTPase activating protein, incorporated in the 17-gene LSC</th></e-45)<>	Rho GTPase activating protein, incorporated in the 17-gene LSC	
		(/		( =,	score which predicts treatment response in AML[9]	
MN1	0.502	(1.1E-23)	0.565	( <e-45)< th=""><th>A transcriptional coactivator, overexpression could induce AML in</th></e-45)<>	A transcriptional coactivator, overexpression could induce AML in	
	0.002	(=:== ==)	0,000	( -=)	mice and predict ATRA resistance in human AML patients[43,44]	
ABCG1	0.504	4 (6.7E-24) 0.610 ( <e-45)< th=""><th>(<e-45)< th=""><th>Belongs to ATP-binding cassette (ABC) superfamily; responsible for</th></e-45)<></th></e-45)<>		( <e-45)< th=""><th>Belongs to ATP-binding cassette (ABC) superfamily; responsible for</th></e-45)<>	Belongs to ATP-binding cassette (ABC) superfamily; responsible for	
		(,	0.010	,5/	important chemoresistance mechanism in AML[45-50]	
					Belongs to ATP-binding cassette (ABC) superfamily; a strong	
ABCA2	0.367	(1.5E-12)	0.507	(2.3E-11)	prognostic biomarker for multidrug resistance in pediatric acute	
					lymphoblastic leukemia[45-50]	
ABCB1	0.353	(1.2E-11)	0.364	(5.2E-6)	Belongs to ATP-binding cassette (ABC) superfamily; responsible for	
5022		, <b></b> /		, <i>-</i> ,	important chemoresistance mechanism in AML[45-50]	
ABCC1	0.310	(3.2E-9)	0.458	(5.2E-9)	Belongs to ATP-binding cassette (ABC) superfamily; responsible for	
5 001	5.515	(5.22.5)	5.,100	(2.22 0)	important chemoresistance mechanism in AML[45-50]	

407

408

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

Figure legends Figure 1. Box plots depicting expression levels of KIAA0125 in healthy controls and various AML subgroups. (a) Patients with AML had significantly higher expression of KIAA0125 than healthy controls; (b) patients who achieved CR after induction chemotherapy had lower expression of BM KIAA0125 at diagnosis than those who did not; and (c, d) patients with AML, M3 had significantly lower expression of KIAA0125 while those with more immature subtype M0 or M1 had significantly higher expression in both NTUH cohort (c) and GSE12662 cohort (d). Figure 2. Kaplan-Meier survival curves stratified by expression of KIAA0125. DFS (a) and OS (b) of the 227 AML patients receiving standard chemotherapy in the NTUH cohort; OS of 201 non-APL patients (c) and 110 cytogenetically normal AML patients (d) who received standard treatment in the NTUH cohort; and OS of 141 patients in the TCGA cohort (e) and GSE12417-GPL96 cohort. Patients with higher KIAA0125 expression had worse clinical outcomes than those with lower expression. Figure 3. GSEA enrichment plots of HSC and LSC signatures and scatter plot of genes positively associated with higher KIAA0125 expression. (a) GSEA enrichment plots show positive association of higher KIAA0125 expression with HSC and LSC signatures curated from several published reports in both the NTUH and TCGA cohorts; (b) the scatter plot reveals the genes strongly correlated to KIAA0125 expression in both the NTUH and TCGA cohorts (pink). The correlation measurement is based on the Spearman's correlation coefficient between the given gene and KIAA0125. The strongly

- 433 correlated genes are defined as their correlation values at top 5% of all genes in both
- 434 cohorts.







